ClinicalTrials.gg
RecruitingNCT06515730RESOLVE-AMIUpdated Jul 1, 2025

Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction

A Phase 4 interventional study of Apixaban and Warfarin in Left Ventricular Thrombus and Acute Myocardial Infarction, sponsored by Karolinska Institutet. Recruiting at 16 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Karolinska Institutet · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Myocardial Infarction by Karolinska Institutet — 2 open to participants now, 4 under way, none of them phase 3. Myocardial Infarction · Karolinska Institutet.

Planned enrollment
4th of 12
212 · median 123
Started
2025
with 1 other
Phase 4
2 of 17
1 open now
Registered
16th of 17
by date

Among the 17 studies in Myocardial Infarction by Karolinska Institutet, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 4, and was the 16th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

2 of the 17 studies in Myocardial Infarction by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Myocardial Infarction by Karolinska Institutet, or all of them as a file.
02

Study summary

The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.

03

Conditions studied

  • Left Ventricular Thrombus
  • Acute Myocardial Infarction

Keywords

  • Apixaban
  • warfarin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the time of signing the
  • LV thrombus confirmed on TTE* day 1-28 after the AMI
  • Signed informed consent
  • Criteria applicable only for female subjects: Women of must provide a negative pregnancy test not be breastfeeding and be willing and able to use highly effective . Women of non-childbearing potential must be 1 year .

Exclusion criteria

Exclusion Criteria:

  • Ongoing* treatment with anticoagulant therapy due to Mechanical heart valve prosthesis Atrial fibrillation with or without significant mitral valve stenosis Venous thromboembolism requiring anticoagulant therapy Thrombophilia requiring anticoagulant therapy Preexisting LV thrombus already treated with anticoagulant therapy Other reasons for anticoagulant therapy
  • High bleeding risk Active non-trivial bleeding Known chronic bleeding disorder Severe anemia defined as \< 80g/L Thrombocytopenia defined as count \< 80 x 10\^9
  • Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or known hepatic insufficiency classified as C or D at randomization
  • Known allergy, intolerance or to either of the study interventions
  • Any for the use of an anticoagulant or listed in the local labelling for apixaban or warfarin.
  • Participation in other study investigating effects and safety of anticoagulant treatment.
  • Known current alcohol or drug abuse
  • Any other condition, as judged by the investigator, that would make the participant unsafe or unsuitable for the study or \< 6 months
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
212 participants (estimated)

Study arms

  • Experimental
    Apixaban

    Apixaban 5 mg twice a day, reduced to 2.5 mg twice a day for participants with any 2 of following criteria: age \> 80 years, serum creatinine \> 133 μmol/L or body weight \<60 kg. Participants with severe renal failure defined as creatinine clearance 15-29 ml/min/1.73 m2, should also receive the reduced dose of 2.5 mg twice a day.

    Drug: Apixaban

  • Active comparator
    Warfarin

    Warfarin 2,5 mg once daily with individual dosing according to coagulation assays with an international normalized ratio (INR) goal of 2.0-3.0. Bridging with low-molecular-weight-heparin with a dose of dalteparin 200 units/kg but maximum 18 000 units or enoxaparin 150 units/kg, until therapeutic INR is recommended.

    Drug: Warfarin

Interventions

  • 5 mg tablet twice a daily with dose reduction according to label

    Also known as: Eliquis

  • 2.5 mg tablet once daily, with individual dosing according to coagulation tests

    Also known as: Waran

06

What researchers measure

Primary outcomes

  1. Number and proportion of participants with thrombus resolution at 3 months

    Thrombus resolution will be evaluated on transthoracic echocardiogram (TTE\*) at 3 months

    Time frame: 3 months

Secondary outcomes

  1. Clinically relevant bleeding at 3 and 12 months

    Clinical relevant bleeding defined as Bleeding Academy Research Consortium (BARC) 2, 3 or 5 bleeding. The BARC bleeding scale ranges from 0 to 5, where 0 is equal to no bleeding, with increasing severity from 1 through 5, where 5 represents fatal bleeding. Major bleeding is most often defined as BARC 3 and 5. BARC 4 bleeding is coronary artery bypass grafting (CABG) related bleeding.

    Time frame: 3 and 12 months

  2. Severe bleeding at 3 and 12 months

    Severe bleeding defined as BARC 3 or 5. For definition of the BARC bleeding scale please see Outcome 2 above.

    Time frame: 3 and 12 months

  3. Separate bleeding outcomes at 3 and 12 months

    Separate bleeding outcomes defined as fatal, intracranial, gastro-intestinal uro-genital or other bleeding

    Time frame: 3 and 12 months

  4. Major adverse cardiovascular outcomes (MACE) at 3 and 12 months

    MACE is defined as a composite of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death

    Time frame: 3 and 12 months

  5. Stroke or systemic embolism at 3 and 12 months

    Composite of ischemic stroke or systemic embolism

    Time frame: 3 and 12 months

  6. LV thrombus status at 12 months

    Recurrence (or in absence of resolution of LV thrombus at 3 months, persistence) of LV thrombus on TTE at 12 months

    Time frame: 12 months

  7. Net adverse clinical outcomes

    Composite of MACE and. BARC 2, 3 or 5 bleeding. For definition of MACE and BARC bleeding scale please see Outcome 2 and 5 above.

    Time frame: 3 and 12 months

07

Study locations

3 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2028, 36 months after the start.

Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 36 months is below that.

Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 23, 2024
StartActual
Apr 8, 2025
Primary completionEst.
Apr 8, 2028
CompletionEst.
Jul 1, 2028
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06515730
Collaborators
Karolinska Trial Alliance, Swedish Heart Lung Foundation, The Swedish Research Council, Stockholm County Council ALF/PPG
Responsible party
Moa Simonsson (MD, PhD, Karolinska Institutet) — Principal investigator
First posted
Jul 23, 2024
Start date
Apr 8, 2025
Primary completion
Apr 8, 2028 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Jul 1, 2025

Study contacts

Eva Olofsson
Contact
moa.simonsson@ki.se
+46707780897
Stina Smetana
Contact
stina.smetana@ki.se
+46725841182
Moa Simonsson, MD, PhD
principal investigator · Department of Medicine Solna, Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion